The Future of Vitiligo Care: Patient Selection, Treatment Access, and the Road Ahead

Segment summary: In this episode titled "The Future of Vitiligo Care: Patient Selection, Treatment Access, and the Road Ahead," moderator Nada Elbuluk, MD, MSc, FAAD and panelist Susan Taylor, MD, FAAD offer a forward-looking discussion on incorporating systemic JAK inhibitors into clinical practice, individualizing patient selection, and ensuring equitable access to emerging therapies.

Dr. Taylor outlines the key factors that will guide clinicians in determining when systemic JAK inhibitors are appropriate. She places patient goals at the center of the decision — specifically, what concerns patients most and what they are most committed to addressing. Disease extent is the second consideration: localized disease may be adequately managed with topical therapy, while widespread generalized vitiligo may warrant systemic intervention. Risk-benefit assessment, including evaluation of cardiovascular risk factors, smoking status, history of thromboembolic disease, and prior malignancy, rounds out the framework.

Importantly, Dr. Taylor notes that psychosocial burden alone can justify systemic therapy, even in patients with relatively limited disease. A patient whose vitiligo is causing significant anxiety, depression, social withdrawal, or occupational impact may benefit from systemic JAK therapy regardless of the extent of their skin involvement.

Dr. Elbuluk highlights an additional and critical role for systemic JAK inhibitors: disease stabilization. She expresses hope that these agents will replace the systemic corticosteroids previously used for rapid disease arrest, sparing patients the adverse effects of long-term steroid use, including diabetes, hypertension, weight gain, and immunosuppression. Dr. Taylor underscores that stabilizing disease — preventing new lesions and halting enlargement of existing patches — must remain the first priority in treatment planning for any patient with active vitiligo.

Dr. Elbuluk closes the series by calling attention to the urgent need for insurance coverage and patient access to these emerging treatments. She emphasizes that advocacy efforts must continue to ensure all eligible patients — regardless of payer status — can benefit from these advances. Both physicians express optimism about the future of vitiligo care, calling this one of the most exciting periods in the field.

Thank you for watching this Dermatology Times DermView series on vitiligo. Please subscribe to our enewsletter for information on upcoming video series

This video series is not sponsored, and has been produce independently by Dermatology Times.